Normoparin (Heparin Sodium)

Heparin Sodium enhances the activity of antithrombin III, which blocks thrombin (factor IIa) and factor Xa. By inhibiting these key enzymes, the drug reduces fibrin generation, thereby preventing new clot formation and allowing the body’s natural fibrinolytic mechanisms to resolve existing clots.

The dosage of Normoparin is determined individually by the prescribing clinician based on the patient’s clinical condition, weight, renal function and laboratory monitoring. Exact dosing regimens are not disclosed here and should follow the prescriber’s orders.

Normoparin should be used in pregnancy only when the potential benefit justifies the potential risk to the fetus. Limited data are available for breastfeeding; the decision to continue therapy should be made by the healthcare provider after weighing risks and benefits.

To order Normoparin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Normoparin (Heparin Sodium) is a short‑acting injectable anticoagulant that acts via antithrombin III, offering rapid onset and easy reversibility with protamine. Compared with oral direct oral anticoagulants, it requires intravenous administration and laboratory monitoring but provides precise control during acute surgical or interventional settings.

Normoparin should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and sterility.

Normoparin is administered by intravenous injection or infusion under the supervision of a qualified healthcare professional. The rate and duration of infusion are guided by laboratory parameters such as activated partial thromboplastin time (aPTT) or anti‑Xa levels, as ordered by the prescriber.

The most serious risks include severe bleeding, heparin‑induced thrombocytopenia (HIT), spinal or epidural hematoma, and paradoxical thrombosis. Prompt recognition of these events and immediate medical attention are essential.

Normoparin is contraindicated in patients with active major bleeding, known hypersensitivity to heparin or its components, and those with a history of heparin‑induced thrombocytopenia. Caution is also advised for patients with severe liver disease, uncontrolled hypertension, or recent major surgery.